Browsing by Author "Bilgin, Burak"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Production of double haploid plants using in vivo haploid techniques in corn
    (Tarım Bilimleri Dergisi, 2019-01-01) Zararsız, Duran; Öztürk, Leyla; Yanıkoğlu, Semra; Turgut, İlhan; Kızık, Sezgin; Bilgin, Burak; TURGUT, İLHAN; Bursa Uludağ Üniversitesi/Ziraat Fakültesi/Tarla Bitkileri Bölümü; AAH-2761-2021
    This research was conducted at the breeding station of the Turkish breeding company Agromar A.S in the city of Bursa in Turkey during the 2013 and 2014 growing seasons. Used from within the same heterotic group crossings, 7 donor materials were obtained during the 2012 winter season in the greenhouse. The inducer line RWK-76xRWS, provided by University of Hohenheim, Germany, was used for generating haploid seeds. The donor and inducer crossing was performed during the 2013 summer season. The haploid selection and chromosome doubling were performed during the 2014 summer season. Seven donors were used for haploid induction which name are DNR1, DNR2, DNR3, DNR4, DNR5, DNR6, DNR7 respectively, from each donor different amount of ear crosses were performed (DNR1:16 ears, DNR2:10 ears, DNR3:10 ears, DNR4:12 ears, DNR5:11 ears, DNR6:13 ears, DNR7: 11 ears). According to the present study, the average induction rate found ranged from 7.1 to 12.8%, and the average seedling survival rate in the greenhouse after colchicine application ranged from 57.9 to 77.6%. After transplanting to the field, 78.3-92.6% of these plants survived. As a result of this research, the chromosome doubling rate ranged from 22.5 to 48.3% depending on the donor material. These result indicates that maternal haploid selection visually is easy. Haploid induction rate (HIR) changes from donor to donor, its mean genotype and environment is effective for HIR. Average chromosome doubling rate is lower than other researchers' results, it is also effected by genotype and chromosome doubling methods.
  • No Thumbnail Available
    Publication
    Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    (Future Medicine Ltd, 2023-05-03) Kahraman, Seda; Erul, Enes; Seyyar, Mustafa; Gumusay, Ozge; Bayram, Ertugrul; Demirel, Burcin Cakan; Acar, Omer; Aksoy, Sercan; Baytemur, Naziyet Kose; Sahin, Elif; Cabuk, Devrim; Basaran, Gul; Paydas, Semra; Yaren, Arzu; Guven, Deniz Can; Erdogan, Atike Pinar; Demirci, Umut; Yasar, Alper; Bayoglu, Ibrahim Vedat; Hizal, Mutlu; Gulbagci, Burcu; Paksoy, Nail; Davarci, Sena Ece; Yilmaz, Funda; Dogan, Ozlem; Orhan, Sibel Oyucu; Kayikcioglu, Erkan; Aytac, Ali; Keskinkilic, Merve; Mocan, Eda Eylemer; Unal, Olcun Umit; Aydin, Esra; Yucel, Hakan; Isik, Deniz; Eren, Onder; Uluc, Basak Oyan; Ozcelik, Melike; Hacibekiroglu, Ilhan; Aydiner, Adnan; Demir, Hacer; Oksuzoglu, Berna; Cilbir, Ebru; Cubukcu, Erdem; Cetin, Bulent; Oktay, Esin; Erol, Cihan; Okutur, Sadi Kerem; Yildirim, Nilgun; Alkan, Ali; Selcukbiricik, Fatih; Aksoy, Asude; Karakas, Yusuf; Ozkanli, Gulhan; Duman, Berna Bozkurt; Aydin, Dincer; Dulgar, Ozgecan; Er, Muhammed Muhiddin; Teker, Fatih; Yavuzsen, Tugba; Aykan, Musa Baris; Inal, Ali; Iriagac, Yakup; Kalkan, Nurhan Onal; Keser, Murat; Sakalar, Teoman; Menekse, Serkan; Kut, Engin; Bilgin, Burak; Karaoglanoglu, Muge; Sunar, Veli; Ozdemir, Ozlem; Turhal, Nazim Serdar; Karadurmus, Nuri; Yalcin, Bulent; Sendur, Mehmet Ali Nahit; OYUCU ORHAN, SİBEL; ÇUBUKÇU, ERDEM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.; 0000-0001-8217-3471 ; ETP-1691-2022; AAJ-8314-2021
    Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.